Show simple item record

Phase I dose-escalation oncology trials with sequential multiple schedules

dc.contributor.authorGünhan, Burak K
dc.contributor.authorWeber, Sebastian
dc.contributor.authorSeroutou, Abdelkader
dc.contributor.authorFriede, Tim
dc.date.accessioned2021-04-18T03:13:56Z
dc.date.available2021-04-18T03:13:56Z
dc.date.issued2021
dc.identifier.urihttp://resolver.sub.uni-goettingen.de/purl?gs-1/17760
dc.description.abstractAbstract Background Conventional methods for phase I dose-escalation trials in oncology are based on a single treatment schedule only. More recently, however, multiple schedules are more frequently investigated in the same trial. Methods Here, we consider sequential phase I trials, where the trial proceeds with a new schedule (e.g. daily or weekly dosing) once the dose escalation with another schedule has been completed. The aim is to utilize the information from both the completed and the ongoing schedules to inform decisions on the dose level for the next dose cohort. For this purpose, we adapted the time-to-event pharmacokinetics (TITE-PK) model, which were originally developed for simultaneous investigation of multiple schedules. TITE-PK integrates information from multiple schedules using a pharmacokinetics (PK) model. Results In a simulation study, the developed approach is compared to the bridging continual reassessment method and the Bayesian logistic regression model using a meta-analytic-predictive prior. TITE-PK results in better performance than comparators in terms of recommending acceptable dose and avoiding overly toxic doses for sequential phase I trials in most of the scenarios considered. Furthermore, better performance of TITE-PK is achieved while requiring similar number of patients in the simulated trials. For the scenarios involving one schedule, TITE-PK displays similar performance with alternatives in terms of acceptable dose recommendations. The R and Stan code for the implementation of an illustrative sequential phase I trial example in oncology is publicly available ( https://github.com/gunhanb/TITEPK_sequential ). Conclusion In phase I oncology trials with sequential multiple schedules, the use of all relevant information is of great importance. For these trials, the adapted TITE-PK which combines information using PK principles is recommended.
dc.language.isoen
dc.publisherBioMed Central
dc.identifier.bibliographicCitationBMC Medical Research Methodology. 2021 Apr 14;21(1):69
dc.rightsopenAccess
dc.titlePhase I dose-escalation oncology trials with sequential multiple schedules
dc.typejournalArticle
dc.identifier.doi10.1186/s12874-021-01218-9
dc.type.versionpublishedVersion
dc.date.updated2021-04-18T03:13:56Z
dc.rights.holderThe Author(s)
dc.bibliographicCitation.volume21
dc.bibliographicCitation.issue1
dc.type.subtypejournalArticle
dc.bibliographicCitation.articlenumber69
dc.bibliographicCitation.journalBMC Medical Research Methodology


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record